GENETIC CHARACTERISTICS OF INFLUENZA A/H3N2 AND В VIRUSES THAT HAD CIRCULATED IN RUSSIA IN 2013 - 2015

Cover Page


Cite item

Full Text

Abstract

Aim. Establish genetic characteristics, carry out phylogenetic analysis and determination of molecular markers of resistance to etiotropic preparations against influenza A/H3N2 and В viruses that had circulated in Russia in 2013 - 2015. Materials and methods. 80 biological samples containing influenza A/H3N2 virus RNA and 31 samples containing influenza В virus RNA were studied. Sequencing of PCR fragments was carried out in ABI-3100 PRIZMTM GeneticAnalyzer (AppliedBiosystems, USA) and using MiSeq (Illumina, USA). Data treatment and analysis was carried out using CLC v.3.6.5., DNASTAR and BioNumerics v.6.5. programs. Results. In 2013 - 2014 A/Texas/50/2012-like clade 3C.3 influenza A/H3N2 viruses dominated, 10% belonged to subclade 3C.2a and 10% - to ЗС.ЗЬ. Most of the viruses (81%) of 2014 - 2015 were of 3C.2a clade, the portion of viruses belonging to ЗС.ЗЬ and ЗС.За was 9 and 10%. Yamagata-like viruses predominated among the studied influenza В viruses, only 1 virus of 2014 - 2015 belonged to Victoria lineage, 1 reassortant of Yamagata and Victoria lineages was detected. Rimantadine-resistance mutation S31N (М2 protein) was detected in all the influenza A/H3N2 viruses. Mutations determining resistance to oseltamivir (NA gene) were not detected in influenza A/H3N2 and В viruses. Conclusion. Increase of influenza morbidity in 2014 - 2015 was determined by the emergence of influenza A/H3N2 and В viruses, antigenically distinct from those that had circulated previously and those included into the vaccine, thus resulting in the WHO decision to change А/ H3N2 and В components of the 2015 - 2016 vaccine. Simultaneous circulation of 2 lineages of influenza В virus and emergence of their reassortants gives evidence on the necessity of use of quadrivalent vaccines, containing both lineages.

About the authors

S. B. Yatsyshina

Central Research Institute of Epidemiology

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. N. Renteeva

Central Research Institute of Epidemiology

Email: noemail@neicon.ru
Russian Federation

A. V. Valdokhina

Central Research Institute of Epidemiology

Email: noemail@neicon.ru
Russian Federation

M. A. Elkina

Central Research Institute of Epidemiology

Email: noemail@neicon.ru
Russian Federation

A. S. Speranskaya

Central Research Institute of Epidemiology

Email: noemail@neicon.ru
Russian Federation

E. V. Pimkina

Central Research Institute of Epidemiology

Email: noemail@neicon.ru
Russian Federation

R. R. Mintaev

Central Research Institute of Epidemiology

Email: noemail@neicon.ru
Russian Federation

M. L. Markelov

Central Research Institute of Epidemiology

Email: noemail@neicon.ru
Russian Federation

V. V. Maleev

Central Research Institute of Epidemiology

Email: noemail@neicon.ru
Russian Federation

References

  1. База данных GISAID EpiFluTM. Электронный ресурс http://flusurver.bii.a-star.edu.sg/ MUTATI ON S/H 3N 2_Human_2013_Switzerland9715293/НА_ 13 8_stat.html.
  2. База данных GISAID EpiFluTM. Электронный ресурс http://flusurver.bii.a-star.edu.sg/ MUTATIONS/H3N2_Human_2013_Switzerland9715293/HA_154_stat.html
  3. Данные НИИ гриппа. Эпидемиологическая ситуация. Лабораторная диагностика гриппа и ОРВИ, http://www.influenza.spb.ru/system/epidemiological_situation/laboratory_ diagnostics/?year=2015&week=22.
  4. Письмо Роспотребнадзора от 30.06.2014 № 01/7281-14-32. Об итогах эпидсезона по гриппу и ОРВИ 2013/2014. http://rospotrebnadzor.ru/upload/iblock/088/pismo-po-itogam-sezona-gripp.pdf.
  5. Письмо Роспотребнадзора от 28.07.2015 № 1042. Об итогах эпидсезона по гриппу и ОРВИ 2014/2015гг и задачах на предстоящий эпидсезон 2015/2016 гг, www.stupenil5. edusite.ru/DswMedia/itogigripp-2015.doc.
  6. Ambrose C.S., Levin MJ. Therationale for quadrivalent influenza vaccines. Hum. Vaccin. Immunother. 2012, 8 (1): 81-88.
  7. Busch M.G., Bateman A.C., Landolt G.A. et al. Identification of amino acids in the HA of H3 influenza viruses that determine infectivity levels in primary swine respiratory epithelial cells. Virus Res. 2008, 133 (2): 269-279.
  8. Chen J.M., Guo Y.J., Wu K.Y. et al. Exploration of the emergence of the Victoria lineage of influenza В virus. Arch. Virol. 2007, 152 (2): 415-422.
  9. Chen R., Holmes E.C. The evolutionary dynamics of human influenza В virus. J. Mol. Evol. 2008, 66 (6): 655-663.
  10. CockbumW.C., Delon P.J., Ferreira W. Origin and progress of the 1968-69 Hong Kong influenza epidemic. Bull. World Health Organ. 1969, 41 (3): 345-348.
  11. ECDC European Centre. Influenza virus characterization summary Europe, July 2012. http:// ecdc.europa.eu/en/publications/Publications/CNRL-July-2012.pdf.
  12. ECDC European Centre. Influenza virus characterization summary Europe, July 2015. http:// ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-july-2015. pdf.
  13. Koel B.F., Burke D.F., Bestebroer T.M. et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013, 342 (6161): 976-979.
  14. Lee М-S., Chen J. S-E. Predicting antigenic variants of influenza A/H3N2 viruses. Emerg. Infect. Dis. 2004, 10 (8): 1385-1390.
  15. Morbidity and Mortality Weekly Report. CDC Centers, USA. http://www.cdc.gov/mmwr.
  16. Review of the 2012-2013 winter influenza season, northern hemisphere. Weekly Epidemiol. Rec. 2013,88 (22): 225-232.
  17. Rota P.A., Wallis T.R., Harmon M.W. et al. Cocirculation of two distinct evolutionary lineages of influenza type В virus since 1983. Virology. 1990, 175 (1): 59-68.
  18. Smith D.J., Lapedes A.S., de Jong J.C. et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004, 305 (5682): 371-376.
  19. Wang Q., Tian X., ChenX., Ma J. Structural basis for receptor specificity of influenza В virus hemagglutinin. Proc. Natl. Acad. Sci. USA. 2007, 104 (43): 16874-16879.
  20. WHO Influenza Centre, London. Recommended composition of influenza virus vaccines for use in the 2013-14 (2014-15) (2015-16) northern hemisphere influenza season. http://www. who.int/influenza/vaccines/virus/recommendations/2013_ 14_north/en/ (2014_ 15), (201516).
  21. WHO Influenza Centre, London. Report prepared for the WHO annual consultation on the composition of influenza vaccine forthe Northern Hemisphere 2015/16.23rd -25th February 2015.
  22. WHO Influenza Centre, St Petersburg, Russia. Digest of Influenza Surveillance in Russia, Seasons 2009-2013. http://www.influenza.spb.ru/files/rii-digest-2013.pdf.
  23. WHO. Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors, http://www.who.int/influenza/gisrs_laboratory/antiviral_sus-ceptibility/avwg2014_nai_substitution_table.pdf.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Yatsyshina S.B., Renteeva A.N., Valdokhina A.V., Elkina M.A., Speranskaya A.S., Pimkina E.V., Mintaev R.R., Markelov M.L., Maleev V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies